Catalent (NYSE:CTLT) Stock Rating Upgraded by Zacks Investment Research

Share on StockTwits

Catalent (NYSE:CTLT) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, Zacks.com reports. The brokerage currently has a $57.00 target price on the stock. Zacks Investment Research‘s target price suggests a potential upside of 12.67% from the stock’s previous close.

According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “

CTLT has been the subject of a number of other reports. Morgan Stanley boosted their price objective on Catalent from $46.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, April 16th. Jefferies Financial Group boosted their price objective on Catalent from $44.00 to $50.00 and gave the company a “hold” rating in a research report on Tuesday, April 16th. UBS Group upgraded Catalent from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $43.00 to $54.00 in a research report on Tuesday, April 16th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research report on Monday, April 15th. Finally, First Analysis restated an “outperform” rating and issued a $49.00 price objective on shares of Catalent in a research report on Tuesday, March 5th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $51.43.

CTLT stock traded up $0.11 during trading on Wednesday, hitting $50.59. 685,600 shares of the company traded hands, compared to its average volume of 861,465. The company has a current ratio of 2.18, a quick ratio of 1.71 and a debt-to-equity ratio of 1.31. The stock has a market cap of $7.37 billion, a P/E ratio of 31.82, a P/E/G ratio of 2.61 and a beta of 1.57. Catalent has a 1 year low of $29.23 and a 1 year high of $51.11.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, May 7th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.07. The company had revenue of $617.50 million during the quarter, compared to analysts’ expectations of $644.88 million. Catalent had a return on equity of 16.78% and a net margin of 6.01%. Catalent’s quarterly revenue was down 1.7% on a year-over-year basis. During the same period last year, the business earned $0.41 earnings per share. On average, research analysts predict that Catalent will post 1.72 earnings per share for the current fiscal year.

In other Catalent news, insider Peter L. Buzy acquired 44,500 shares of the business’s stock in a transaction dated Wednesday, May 29th. The stock was acquired at an average cost of $45.13 per share, for a total transaction of $2,008,285.00. Following the completion of the transaction, the insider now directly owns 44,500 shares of the company’s stock, valued at $2,008,285. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Donald E. Morel, Jr. acquired 10,000 shares of the business’s stock in a transaction dated Wednesday, May 15th. The stock was acquired at an average price of $44.44 per share, with a total value of $444,400.00. The disclosure for this purchase can be found here. Insiders bought 56,500 shares of company stock valued at $2,542,845 over the last 90 days. Company insiders own 1.40% of the company’s stock.

Several large investors have recently modified their holdings of the company. Nordea Investment Management AB lifted its stake in shares of Catalent by 1.3% in the 1st quarter. Nordea Investment Management AB now owns 109,340 shares of the company’s stock valued at $4,438,000 after purchasing an additional 1,350 shares during the last quarter. GYL Financial Synergies LLC acquired a new position in shares of Catalent in the 1st quarter valued at $217,000. Westfield Capital Management Co. LP lifted its stake in shares of Catalent by 29.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 448,946 shares of the company’s stock valued at $18,223,000 after purchasing an additional 101,645 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Catalent by 1.9% in the 1st quarter. Champlain Investment Partners LLC now owns 3,913,500 shares of the company’s stock valued at $158,849,000 after purchasing an additional 74,670 shares during the last quarter. Finally, Lazard Asset Management LLC lifted its stake in shares of Catalent by 149.5% in the 1st quarter. Lazard Asset Management LLC now owns 741,200 shares of the company’s stock valued at $30,085,000 after purchasing an additional 444,120 shares during the last quarter. 96.85% of the stock is currently owned by hedge funds and other institutional investors.

About Catalent

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Cash Flow Analysis in Stock Selection

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MKM Partners Lowers ADTRAN  Price Target to $17.00
MKM Partners Lowers ADTRAN Price Target to $17.00
Apple  PT Raised to $180.00 at Nomura
Apple PT Raised to $180.00 at Nomura
Advaxis  Lowered to “Hold” at ValuEngine
Advaxis Lowered to “Hold” at ValuEngine
Zacks Investment Research Upgrades Atlas Air Worldwide  to “Hold”
Zacks Investment Research Upgrades Atlas Air Worldwide to “Hold”
Apple  Raised to “Outperform” at Raymond James
Apple Raised to “Outperform” at Raymond James
Zacks Investment Research Lowers Agilysys  to Hold
Zacks Investment Research Lowers Agilysys to Hold


© 2006-2019 Ticker Report